Almirall Toekomstige groei
Future criteriumcontroles 4/6
Almirall zal naar verwachting groeien in winst en omzet met respectievelijk 28% en 8.4% per jaar. De winst per aandeel zal naar verwachting groeien met 22% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 10% zijn.
Belangrijke informatie
28.0%
Groei van de winst
21.96%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 20.3% |
| Inkomstengroei | 8.4% |
| Toekomstig rendement op eigen vermogen | 10.02% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 22 May 2026 |
Recente toekomstige groei-updates
Analyseartikel • Nov 13
Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a good week for Almirall, S.A. ( BME:ALM ) shareholders, because the company has just released its latest...Analyseartikel • Jul 29
The Almirall, S.A. (BME:ALM) Interim Results Are Out And Analysts Have Published New Forecasts
Almirall, S.A. ( BME:ALM ) came out with its interim results last week, and we wanted to see how the business is...Recent updates
Narratiefupdate • Feb 03
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have nudged their price target on Almirall higher to €13.91 from €13.69, reflecting updated assumptions on revenue growth, profit margins and future P/E, despite a recent downgrade in stance from BNP Paribas. Analyst Commentary Analysts are sending mixed signals on Almirall, with a higher price target sitting alongside a more cautious rating.Narratiefupdate • Jan 19
ALM: Future Re-Rating Will Rely On Dermatology Pipeline And Execution
Analysts slightly trimmed their price target for Almirall to €13.69 from €13.86, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Almirall plans to start a phase III study in the first half of 2026 evaluating Lebrikizumab (Ebglyss) for nummular eczema.Narratiefupdate • Jan 05
ALM: Future Re-Rating Will Depend On Pipeline Execution And Ebglyss Ramp-Up
Narrative update on Almirall Analysts have raised their price target on Almirall to €14.50, citing what they see as a still-compelling valuation, along with expectations for Ebglyss ramp-up, upcoming clinical readouts, and potential in-licensing and M&A to support the mid-stage pipeline. Analyst Commentary Recent research points to a target price of €14.50 for Almirall, with the view that the shares still offer a compelling entry point despite a prior rebound in the stock.Narratiefupdate • Dec 17
ALM: Future Re-Rating Will Hinge On Ebglyss Uptake And Pipeline Delivery
Analysts have modestly raised their price target on Almirall to EUR 14.50, citing expectations for a continued valuation re-rating supported by the ramp up of Ebglyss, upcoming clinical readouts, and potential in-licensing and M&A to bolster the mid-stage pipeline. Analyst Commentary Analyst views on Almirall remain broadly positive, with recent coverage highlighting both upside drivers and execution risks as the company advances its dermatology portfolio.Analyseartikel • Dec 08
Market Cool On Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 2.6x is worth a...Narratiefupdate • Dec 03
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have modestly raised their 12 month price target for Almirall to EUR 14.50, citing expectations that a continued re rating driven by Ebglyss ramp up, upcoming clinical readouts, and potential in licensing and M&A could support upside from current levels. Analyst Commentary Analysts note that Almirall's investment case is increasingly driven by visible growth levers in medical dermatology, but also caution that execution on product ramps and pipeline milestones will be critical to sustaining the recent share price rebound.Narratiefupdate • Nov 19
ALM: Pipeline Milestones And Product Launch Momentum Will Drive Re-Rating
Analysts have increased their price target for Almirall from €13.30 to €13.87. They cite a compelling valuation, strong pipeline prospects, and expectations for continued growth driven by product launches and strategic developments.Analyseartikel • Nov 17
Almirall's (BME:ALM) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Almirall, S.A.'s ( BME:ALM ) stock...Analyseartikel • Nov 13
Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a good week for Almirall, S.A. ( BME:ALM ) shareholders, because the company has just released its latest...Analyseartikel • Aug 19
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Jul 29
The Almirall, S.A. (BME:ALM) Interim Results Are Out And Analysts Have Published New Forecasts
Almirall, S.A. ( BME:ALM ) came out with its interim results last week, and we wanted to see how the business is...Nieuw narratief • Jul 22
European Demographics Will Drive Advancements In Dermatology Treatments
Strong specialty product launches and robust R&D pipeline are expected to drive growth, improve margins, and boost Almirall's market position in innovative dermatology.Analyseartikel • May 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 44% Above Its Share Price
Key Insights The projected fair value for Almirall is €14.08 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Mar 27
Why We're Not Concerned About Almirall, S.A.'s (BME:ALM) Share Price
With a median price-to-sales (or "P/S") ratio of close to 2.2x in the Pharmaceuticals industry in Spain, you could be...Analyseartikel • Mar 03
Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are
Almirall, S.A. ( BME:ALM ) recently posted some strong earnings, and the market responded positively. Our analysis...Analyseartikel • Feb 12
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Dec 10
Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Analyseartikel • Nov 14
Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Almirall, S.A. ( BME:ALM ) shareholders are probably feeling a little disappointed, since its shares fell 2.9% to €8.52...Analyseartikel • Nov 06
Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Sep 07
Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)
You may think that with a price-to-sales (or "P/S") ratio of 2x Almirall, S.A. ( BME:ALM ) is a stock worth checking...Analyseartikel • Jul 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Almirall fair value estimate is €18.31 Current share price of...Analyseartikel • Apr 24
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Analyseartikel • Mar 20
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Dec 15
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analyseartikel • Oct 03
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?
Key Insights Almirall's estimated fair value is €11.86 based on 2 Stage Free Cash Flow to Equity Almirall's €9.37 share...Analyseartikel • Aug 24
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Jul 05
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?
Key Insights Almirall's estimated fair value is €11.37 based on 2 Stage Free Cash Flow to Equity Current share price of...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 1,486 | 157 | 231 | 323 | 9 |
| 12/31/2027 | 1,365 | 122 | 176 | 274 | 11 |
| 12/31/2026 | 1,230 | 85 | 144 | 232 | 11 |
| 3/31/2026 | 1,121 | 40 | 49 | 196 | N/A |
| 12/31/2025 | 1,115 | 46 | 37 | 174 | N/A |
| 9/30/2025 | 1,085 | 42 | 30 | 201 | N/A |
| 6/30/2025 | 1,054 | 21 | 24 | 152 | N/A |
| 3/31/2025 | 1,028 | 24 | 5 | 164 | N/A |
| 12/31/2024 | 991 | 10 | -1 | 161 | N/A |
| 9/30/2024 | 953 | -45 | -23 | 149 | N/A |
| 6/30/2024 | 932 | -35 | -115 | 103 | N/A |
| 3/31/2024 | 915 | -39 | -48 | 116 | N/A |
| 12/31/2023 | 899 | -38 | -66 | 93 | N/A |
| 9/30/2023 | 907 | 7 | -23 | 101 | N/A |
| 6/30/2023 | 898 | -11 | 23 | 156 | N/A |
| 3/31/2023 | 882 | -8 | 37 | 154 | N/A |
| 12/31/2022 | 879 | 4 | 39 | 155 | N/A |
| 9/30/2022 | 864 | 9 | 105 | 177 | N/A |
| 6/30/2022 | 856 | 29 | 98 | 180 | N/A |
| 3/31/2022 | 843 | -50 | 82 | 159 | N/A |
| 12/31/2021 | 837 | -41 | 163 | 234 | N/A |
| 9/30/2021 | 814 | -22 | 204 | 288 | N/A |
| 6/30/2021 | 809 | -11 | 145 | 196 | N/A |
| 3/31/2021 | 790 | 55 | 122 | 198 | N/A |
| 12/31/2020 | 814 | 74 | 36 | 113 | N/A |
| 9/30/2020 | 849 | 63 | 72 | 212 | N/A |
| 6/30/2020 | 872 | 86 | 49 | 194 | N/A |
| 3/31/2020 | 926 | 121 | 158 | 296 | N/A |
| 12/31/2019 | 911 | 106 | N/A | 276 | N/A |
| 9/30/2019 | 858 | 85 | N/A | 190 | N/A |
| 6/30/2019 | 884 | 88 | N/A | 181 | N/A |
| 3/31/2019 | 789 | 80 | N/A | 138 | N/A |
| 12/31/2018 | 811 | 78 | N/A | 143 | N/A |
| 9/30/2018 | 714 | -111 | N/A | 170 | N/A |
| 6/30/2018 | 730 | -179 | N/A | 133 | N/A |
| 3/31/2018 | 687 | -293 | N/A | 82 | N/A |
| 12/31/2017 | 677 | -304 | N/A | 6 | N/A |
| 9/30/2017 | 735 | -128 | N/A | -89 | N/A |
| 6/30/2017 | 755 | -78 | N/A | -13 | N/A |
| 3/31/2017 | 821 | 73 | N/A | 12 | N/A |
| 12/31/2016 | 822 | 75 | N/A | 105 | N/A |
| 9/30/2016 | 778 | 162 | N/A | 151 | N/A |
| 6/30/2016 | 743 | 154 | N/A | 122 | N/A |
| 3/31/2016 | 721 | 111 | N/A | 114 | N/A |
| 12/31/2015 | 738 | 132 | N/A | 171 | N/A |
| 9/30/2015 | 783 | 479 | N/A | 761 | N/A |
| 6/30/2015 | 802 | 488 | N/A | 748 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei ALM ( 28% per jaar) ligt boven de spaarquote ( 2.7% ).
Winst versus markt: De winst van ALM ( 28% per jaar) zal naar verwachting sneller groeien dan de Spanish markt ( 11.6% per jaar).
Hoge groeiwinsten: De winst van ALM zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van ALM ( 8.4% per jaar) zal naar verwachting sneller groeien dan de markt Spanish ( 6.4% per jaar).
Hoge groei-inkomsten: De omzet van ALM ( 8.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen ALM zal naar verwachting over 3 jaar laag zijn ( 10 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/25 05:26 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Almirall, S.A. wordt gevolgd door 27 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |